Retrospective observational study taking an inventory of the KRAS test in 2011 in patients with metastatic colorectal cancer having recently started a first-line treatment FRESH-PEF73327-en Juliette LONGIN Retrospective observational study taking an inventory of the KRAS test in 2011 in patients with metastatic colorectal cancer having recently started a first-line treatment Flash-KRAS FRESH-PEF73327-en 73327 FRESH-PEF73327 Pierre LAURENT-PUIG Astrid LIEVRE Michel GUIU Jean-Louis MERLIN Jean-Christophe SABOURIN Pascal ARTRU Michel DUCREUX Jérôme VIGUIER MERCK SANTE Epidemiology France Portal (PEF) MERCK SANTE null Flash-KRAS Colorectal cancer Oncology Neoplasms Evaluate the KRAS test prescription rate in patients starting a first-line treatment for metastatic colorectal cancer. Secondary objectives: - Describe the potential reasons for not prescribing this test - Describe and analyse the clinical characteristics of patients and treatments planned and received in first-line metastatic treatment - Describe and analyse the time frame for obtaining the result of the KRAS test and the channel (who makes the request and when) and the therapeutic attitude adopted during this period - Analyse the impact of the availability of the KRAS test and its result on the therapeutic choice of the physician - Describe the technic used for the analysis, the type of mutation (if available) and the method for reporting the results to the clinicians (report of the results) null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Each participating centre had to select the exhaustiveness of the patients seen in consultation during the study period, meeting all of the following criteria: - Patients aged 18 years or older, - Patients with histologically proven metastatic colorectal cancer, - Patients for whom a metastatic first-line treatment was initiated between 01/01/2011 and 27/03/2011, - Patients seen in consultation during the official 2-week study selection period. Clinical data Participant-reported health data Biological data Health care consumption and services Other Through independent healthcare practitioners Through organizations (health services or institutions schools businesses etc.) [500-1000[ individuals Interview with the participant (including clinical) Observational Study Observational Study n=538 patients (160 centres) Unknown To be defined Access on specific project only